P3 Health Partners Reports 4% Revenue Decline to $373.2 Million, Adjusted EBITDA Loss of $22.2 Million in Q1 2025

Reuters
16 May
P3 Health Partners Reports 4% Revenue Decline to $373.2 Million, Adjusted EBITDA Loss of $22.2 Million in Q1 2025

P3 Health Partners Inc. reported its financial results for the first quarter of 2025, showing a total revenue of $373.2 million, a decrease of 4% compared to $388.5 million in the same quarter of the previous year. The medical margin for the quarter was $17.2 million, significantly down from $36.6 million in the first quarter of the prior year, with the medical margin PMPM at $49 compared to $96 previously. This decrease included a negative $23 million net impact from prior year claims related to a single payer. The company also reported an Adjusted EBITDA loss of $22.2 million, compared to a loss of $19.8 million in the previous year's first quarter. The Adjusted EBITDA loss PMPM was $64, up from $52 in the prior year, which included a negative $9 million net impact from prior year claims and retroactive adjustments. P3 Health Partners affirmed its 2025 guidance, noting that its physician-led care enablement model is contributing to improvements in quality measures and cost management, with three out of four markets achieving breakeven or better in the first quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. P3 Health Partners Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-025928), on May 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10